Chemotherapy of metastatic XXXX . A retrospective review.

@entity1 @entity632 @entity5 @entity786 @entity189 @entity3
@entity189 ( @entity189 ) is a rare malignancy of the skin. though many @entity1 with @entity189 die of disseminated @entity3 , little is known regarding the value of systemic chemotherapy for this disease. We reviewed the records of 20 @entity1 with metastatic @entity189 who were treated with chemotherapy at Memorial Hospital between 1968 and 1983. A large variety of drugs were given. Although only a few @entity1 were treated with any given regimen, metastatic @entity189 appears to be poorly responsive to a wide variety of chemotherapeutic regimens. Five major responses were observed in 30 chemotherapy trials performed in 17 @entity1 with measurable/evaluable disease. No @entity1 responded to single agent therapy alone. In this small group of @entity1 , @entity189 appears to be a relatively chemotherapy resistant @entity5 . Larger, group-wide or inter-group trials are needed to prospectively evaluate the use of chemotherapy in this disease. @entity632 and @entity786 , the two drugs used most commonly in those combinations where responses were seen, appear to be reasonable choices for initial treatment of @entity1 with @entity3 . Our review does not provide data to support the empiric use of chemotherapy in an adjuvant setting.
